알피바이오

314140KOSDAQ의약품 제조업

67.5 / 100

Reference Date: 2026-04-13

Financial Score28.5 / 40

News Sentiment20.0 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Declined 9.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Alpibio produces and sells pharmaceuticals (cold medicine, pain relievers) and health functional foods (omega-3, diet supplements) in various forms, including soft capsules, through OEM/ODM models. It holds over 60% of the domestic pharmaceutical soft capsule market and is rapidly growing its health functional food sales, driven by market expansion and R&D efforts with numerous patents.

Number of Employees

534people

Average Salary

37.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.07Industry Average 14.806.5Point

Lower than industry avg (good)

PBR

0.48Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE

4.47Industry Average 4.424.0Point

In line with industry avg

Debt Ratio

4.34Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲361.4% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.1% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 80

Positive
[바이오사이언스] '오운완' 2040이 젤라틴 챙기는 이유…"99% 순...
2040 세대를 중심으로 운동 후 회복 및 관절 보호를 위한 젤라틴 젤리형 보충제 수요가 확산되고 있으며, 이는 알피바이오의 젤리형 제품 개발 및 상용화에 긍정적인 시장 환경을 제공합니다.

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 5,990Won52-week high 8,01052-week low 5,180

1-month return1.0Point

1m -9.24% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

9 totalPositive 1Neutral 8Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01
Neutral정기주주총회결과2026-03-31
Neutral대표이사변경2026-03-31
Neutral사업보고서 (2025.12)2026-03-23
Neutral감사보고서제출2026-03-23